{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000095","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.200688+00:00","generated_at":"2026-06-15T02:47:48.075100+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Centessa reports Q1 net loss $50.7M, cash $346.2M; advancing SerpinPC, LB101 trials","bullets":["Cash $346.2M as of Mar 31, expected to fund operations into 2026; no draw on Oberland credit facility.","Net loss attributable to shareholders $50.7M vs $54.5M YoY; R&D $32.8M (down 11%), G&A $16.1M (up 12%).","SerpinPC registration program for hemophilia B ongoing; PRESent-5 enrolling; PRESent-2/3 dosing expected H2 2023.","LB101 (PD-L1xCD47 LockBody) Phase 1/2a first-in-human trial dosing subjects for solid tumors.","ORX750 (OX2R agonist for narcolepsy) in IND-enabling activities; preclinical data planned at 2023 scientific meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000095","json":"https://secwatch.observer/filing/0001847903-23-000095.json","markdown":"https://secwatch.observer/filing/0001847903-23-000095.md","text":"https://secwatch.observer/filing/0001847903-23-000095.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000095/0001847903-23-000095-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000095/cnta-20230512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T02:47:48.075100+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab0a1a77c476e3adebece41c0b5152c1e98b86e6","claim":"Centessa Pharmaceuticals plc reported the first quarter ended March 31, 2023 results: net income Net Loss Attributable to Ordinary Shareholders: $50.7 million.","evidence_excerpt":"Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000095/0001847903-23-000095-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Net income","value":"Net Loss Attributable to Ordinary Shareholders: $50.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}